Oruka Therapeutics ORKA
$95.81 −$1.76 (-1.80%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $95.81 0.00%
Open$95.86
Prev close$97.57
Day range$93.30 – $97.24
Volume1.98M
Market cap$6.50B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$62.14M-82.2% YoY
Net profit-$49.97M-65.0% YoY
Diluted EPS-$0.63-14.5% YoY
Free cash flow-$44.41M-104.6% YoY
Operating cash flow-$44.33M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Profitability & balance sheet
Return on equity-18.2%
Return on assets-17.5%
Return on invested capital-21.7%
Current ratio29.62
Liabilities / assets2.8%
Cash & investments$920.28M
Total debt$2.09M
Net cash (debt)$918.18M
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Net cash flow from investing | -$159.40M | -$410.95M | -$14.44M | -$22.02M | -$96.75M |
| -Change in Other Current Liabilities | -$156,000.00 | -$138,000.00 | -$125,000.00 | $20,000.00 | -$448,000.00 |
| -Change in Other Current Assets | $0.00 | -$25,000.00 | $0.00 | $0.00 | -$60,000.00 |
| -Change in Payables and Accrued Expense | $8.64M | $6.35M | $1.20M | $4.16M | $1.93M |
| -Change in Prepaid Assets | -$10.22M | -$4.64M | $461,000.00 | -$805,000.00 | -$3.97M |
| Change in Working Capital | -$1.73M | $1.54M | $1.53M | $3.37M | -$2.56M |
| Other Non-Cash Items | -$1.81M | -$806,000.00 | -$303,000.00 | -$524,000.00 | -$4.55M |
| Depreciation & Depletion & Amortization | $49,000.00 | $43,000.00 | $43,000.00 | $28,000.00 | $83,000.00 |
| Net Income from Continuing Operations | -$49.97M | -$41.21M | -$31.82M | -$29.58M | -$105.43M |
| Net cash flow from continuing operations | -$44.33M | -$33.15M | -$23.58M | -$22.59M | -$88.21M |
| Operating Cash Flow | -$44.33M | -$33.15M | -$23.58M | -$22.59M | -$88.21M |
| Net Cash Flow from Continuing Investing Activities | -$159.40M | -$410.95M | -$14.44M | -$22.02M | -$96.75M |
| Net PPE Purchase and Sale | -$83,000.00 | $0.00 | -$73,000.00 | -$63,000.00 | -$209,000.00 |
| Net Investment Purchase and Sale | -$159.32M | -$410.95M | -$14.36M | -$21.96M | -$96.54M |
| Financing Cash Flow | $126.77M | $663.04M | $40.60M | $298,000.00 | $170.32M |
| Net Cash Flow from Continuing Financing Activities | $126.77M | $663.04M | $40.60M | $298,000.00 | $170.32M |
| Net Issuance Payments Of Debt | $0.00 | – | – | -$109,000.00 | $0.00 |
| Net Common Stock Issuance | $126.77M | $4.37M | $40.60M | $671,000.00 | $671,000.00 |
| Net Preferred Stock Issuance | $0.00 | – | – | $0.00 | $0.00 |
| Ending Cash Balance | $191.52M | $268.47M | $49.52M | $46.94M | $46.94M |
| Net Change in Cash | -$76.95M | $218.95M | $2.59M | -$44.32M | -$14.64M |
| Beginning Cash Balance | $268.47M | $49.52M | $46.94M | $91.25M | $61.58M |
| Free Cash Flow | -$44.41M | -$33.15M | -$23.65M | -$22.66M | -$88.42M |
| Net Other Financing Charges | – | – | – | -$264,000.00 | $169.64M |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| -Gross PPE | $3.10M | $2.69M | $2.01M | $2.12M | $2.12M |
| Investments and Advances | $286.31M | $252.02M | $107.12M | $142.54M | $142.54M |
| -Available for Sale Securities | $286.31M | $252.02M | $107.12M | $142.54M | $142.54M |
| Other Non-Current Assets | $128,000.00 | $128,000.00 | $103,000.00 | $103,000.00 | $103,000.00 |
| Total Liabilities | $33.88M | $24.85M | $17.76M | $16.69M | $16.69M |
| Total Current Liabilities | $31.78M | $22.97M | $16.63M | $15.37M | $15.37M |
| Payables | $14.43M | $7.95M | $6.67M | $4.16M | $4.16M |
| -Accounts Payable | $14.38M | $7.95M | $3.66M | $4.16M | $4.16M |
| -Due to Related Parties Current | $50,000.00 | $0.00 | $3.00M | $9,000.00 | $9,000.00 |
| Current Accrued Expenses | $11.93M | $11.42M | $7.58M | $5.33M | $5.33M |
| Short-Term Debt and Capital Lease Obligation | $838,000.00 | $669,000.00 | $680,000.00 | $619,000.00 | $619,000.00 |
| Net PPE | $3.10M | $2.69M | $2.01M | $2.12M | $2.12M |
| Total Non-Current Assets | $289.53M | $254.84M | $109.23M | $144.76M | $144.76M |
| -Short Term Investments | $728.76M | $605.09M | $339.31M | $290.11M | $290.11M |
| -Cash and Cash Equivalents | $191.52M | $268.47M | $49.52M | $46.94M | $46.94M |
| -Current Capital Lease Obligation | $838,000.00 | $669,000.00 | $680,000.00 | $619,000.00 | $619,000.00 |
| Total Non-Current Liabilities | $2.09M | $1.88M | $1.13M | $1.31M | $1.31M |
| Long Term Debt and Capital Lease Obligation | $2.09M | $1.88M | $1.13M | $1.31M | $1.31M |
| -Long Term Capital Lease Obligation | $2.09M | $1.88M | $1.13M | $1.31M | $1.31M |
| Total Equity | $1.20B | $1.11B | $486.72M | $471.93M | $471.93M |
| Stockholders' Equity | $1.20B | $1.11B | $486.72M | $471.93M | $471.93M |
| Capital Stock | $2.09M | $2.99M | $2.98M | $2.98M | $2.98M |
| -Common Stock | $67,000.00 | $61,000.00 | $50,000.00 | $49,000.00 | $49,000.00 |
| -Preferred Stock | $2.02M | $2.93M | $2.93M | $2.93M | $2.93M |
| Additional Paid-In Capital | $1.51B | $1.38B | $705.20M | $657.56M | $657.56M |
| Gains/Losses Not Affecting Retained Earnings | -$5.04M | -$1.70M | -$480,000.00 | $546,000.00 | $546,000.00 |
| Retained Earnings | -$312.15M | -$262.18M | -$220.98M | -$189.16M | -$189.16M |
| Total Assets | $1.23B | $1.14B | $504.48M | $488.62M | $488.62M |
| Other Current Assets | $21.22M | $11.00M | $6.42M | $6.81M | $6.81M |
| Total Current Assets | $941.49M | $884.56M | $395.25M | $343.86M | $343.86M |
| Cash and Cash Equivalents & Short-Term Investments | $920.28M | $873.56M | $388.83M | $337.04M | $337.04M |
| Convertible preferred securities | – | $2.93M | $2.93M | $0.00 | $0.00 |
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Pretax Profit | -$49.97M | -$41.21M | -$31.82M | -$29.58M | -$105.43M |
| Other Non-Operating Income (Expenses) | $5,000.00 | $4,000.00 | $8,000.00 | -$1,000.00 | -$12,000.00 |
| Other Income (Expense) | $5,000.00 | $4,000.00 | $8,000.00 | -$1,000.00 | -$12,000.00 |
| Non-Operating Interest Income | $12.17M | $8.90M | $4.61M | $4.85M | $16.63M |
| Net Non-Operating Interest Income (Expense) | $12.17M | $8.90M | $4.61M | $4.85M | $16.63M |
| Operating Profit | -$62.14M | -$50.11M | -$36.43M | -$34.43M | -$122.05M |
| Research & Development | $53.70M | $43.26M | $29.15M | $27.64M | $100.64M |
| -General & Admin Expense | $8.44M | $6.85M | $7.29M | $6.79M | $21.41M |
| Selling and Admin Expenses | $8.44M | $6.85M | $7.29M | $6.79M | $21.41M |
| Operating Expense | $62.14M | $50.11M | $36.43M | $34.43M | $122.05M |
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Profit | -$49.97M | -$41.21M | -$31.82M | -$29.58M | -$105.43M |
| Profit from Continuing Operations | -$49.97M | -$41.21M | -$31.82M | -$29.58M | -$105.43M |
| Net Income to Parent Company | -$49.97M | -$41.21M | -$31.82M | -$29.58M | -$105.43M |
| Diluted EPS | -$0.63 | -$0.55 | -$0.48 | -$0.45 | -$1.85 |
| Basic EPS | -$0.63 | -$0.55 | -$0.48 | -$0.45 | -$1.85 |
| Net Income to Common Stockholders | -$49.97M | -$41.21M | -$31.82M | -$29.58M | -$105.43M |
| Non-Operating Interest Expense | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on ORKA.
Sign in to join the discussion.